Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) has earned an average rating of “Hold” from the twenty-two brokerages that are covering the company. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $26.41.
Several equities analysts have recently issued reports on VRX shares. Deutsche Bank AG decreased their price target on Valeant Pharmaceuticals Intl from $20.00 to $19.00 and set a “hold” rating on the stock in a research note on Tuesday, March 7th. BTIG Research reiterated a “neutral” rating on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, February 9th. Barclays PLC reiterated a “hold” rating and issued a $34.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, February 9th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $22.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, February 28th.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://sleekmoney.com/valeant-pharmaceuticals-intl-inc-vrx-receives-26-41-consensus-pt-from-analysts/1739462.html.
In related news, Director Schutter Richard U. De bought 10,000 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were purchased at an average cost of $10.80 per share, with a total value of $108,000.00. Following the acquisition, the director now owns 25,190 shares of the company’s stock, valued at $272,052. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Paul Herendeen bought 24,000 shares of the business’s stock in a transaction on Tuesday, March 14th. The shares were bought at an average cost of $10.72 per share, for a total transaction of $257,280.00. Following the completion of the acquisition, the chief financial officer now directly owns 174,000 shares in the company, valued at approximately $1,865,280. The disclosure for this purchase can be found here. Insiders have acquired a total of 3,034,000 shares of company stock worth $32,825,280 over the last ninety days. Company insiders own 16.37% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in VRX. Verde Servicos Internacionais S.A. bought a new position in shares of Valeant Pharmaceuticals Intl during the first quarter valued at approximately $271,000. Capstone Asset Management Co. increased its position in shares of Valeant Pharmaceuticals Intl by 13.6% in the first quarter. Capstone Asset Management Co. now owns 32,988 shares of the specialty pharmaceutical company’s stock worth $364,000 after buying an additional 3,940 shares in the last quarter. Gulf International Bank UK Ltd increased its position in shares of Valeant Pharmaceuticals Intl by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 98,323 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 1,100 shares in the last quarter. Searle & CO. acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $972,000. Finally, Norges Bank acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $39,286,000. 64.34% of the stock is currently owned by hedge funds and other institutional investors.
Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.25% during midday trading on Monday, reaching $9.48. The company had a trading volume of 9,002,316 shares. The stock has a 50-day moving average price of $11.89 and a 200 day moving average price of $16.05. Valeant Pharmaceuticals Intl has a 12-month low of $9.43 and a 12-month high of $38.50. The company’s market capitalization is $3.30 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 EPS for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.06. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.34 billion. During the same quarter last year, the company earned $1.55 EPS. The company’s revenue was down 12.9% on a year-over-year basis. Equities analysts forecast that Valeant Pharmaceuticals Intl will post $3.89 EPS for the current year.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/valeant-pharmaceuticals-intl-inc-vrx-receives-26-41-consensus-pt-from-analysts/1739462.html
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.